SVRA: Savara Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
182 institutions reported holding $1.38B of Savara Inc on Form 13F (187 the quarter before). 22 opened a new position and 26 sold out. Shares held by institutions: +6%.
| Largest holders | Shares | Value |
|---|---|---|
| NEA Management Company, LLC | 24,471,264 | $150.74M |
| Bain Capital Life Sciences Investors, LLC | 17,600,621 | $108.42M |
| Venrock Adviser, LLC | 14,745,943 | $90.84M |
| Nantahala Capital Management, LLC | 13,953,620 | $85.95M |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 13,569,000 | $83.59M |
| BlackRock, Inc. | 12,494,498 | $76.97M |
| TCG Crossover Management, LLC | 12,362,205 | $76.15M |
| Frazier Life Sciences Management, L.P. | 9,720,852 | $59.88M |
| Polar Capital Holdings Plc | 9,541,786 | $58.78M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,932,545 | $48.86M |
Clinical trial readouts
1 Phase 2 or 3 trials by Savara Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-06 (est.) | Molgramostim | Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | 5 | Recruiting | NCT06431776 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.